tiprankstipranks
Blurbs

Analysts Have Conflicting Sentiments on These Healthcare Companies: Anavex Life Sciences (AVXL) and Biohaven Pharmaceutical Holding Co (BHVN)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Anavex Life Sciences (AVXLResearch Report) and Biohaven Pharmaceutical Holding Co (BHVNResearch Report).

Anavex Life Sciences (AVXL)

JonesTrading analyst Soumit Roy reiterated a Buy rating on Anavex Life Sciences today and set a price target of $40.00. The company’s shares closed last Tuesday at $7.69, close to its 52-week low of $7.29.

According to TipRanks.com, Roy is a 3-star analyst with an average return of 3.9% and a 29.2% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Adaptimmune Therapeutics, and Actinium Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Anavex Life Sciences with a $41.00 average price target.

See the top stocks recommended by analysts >>

Biohaven Pharmaceutical Holding Co (BHVN)

H.C. Wainwright analyst Douglas Tsao downgraded Biohaven Pharmaceutical Holding Co to Hold today and set a price target of $148.50. The company’s shares closed last Tuesday at $140.00, close to its 52-week high of $151.51.

According to TipRanks.com, Tsao is a 2-star analyst with an average return of 0.1% and a 38.4% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Cerevel Therapeutics Holdings, Praxis Precision Medicines, and Protagonist Therapeutics.

Biohaven Pharmaceutical Holding Co has an analyst consensus of Moderate Buy, with a price target consensus of $153.70, implying a 9.8% upside from current levels. In a report released today, SVB Securities also downgraded the stock to Hold with a $150.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on AVXL:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed